# 2025-23702: Medicare's New Trick: Benchmarking Drugs Against Global Prices

2025-23702, Global Benchmark for Efficient Drug Pricing (GLOBE) Model, is a Federal Register proposed rule from Health and Human Services Department, Centers for Medicare & Medicaid Services published 2025-12-23, effective 2026-10-01; deemed significant under Executive Order 12866 (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2025-23702
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-23702
- Title: Global Benchmark for Efficient Drug Pricing (GLOBE) Model
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Centers for Medicare & Medicaid Services
- Citation: 90 FR 60244
- Published: 2025-12-23
- Effective: 2026-10-01
- Comments close: not stated
- Significant: yes (OIRA_API)
- Touches household money: no
- Regulation identifier numbers: 0938-AV66
- Last updated: 2026-11-17

## In one line

Medicare's New Trick: Benchmarking Drugs Against Global Prices

## Summary

The GLOBE Model is a new plan to help Medicare pay less for certain medicines by using a global price benchmark. This change affects Medicare patients and drug makers, aiming to save money while keeping care quality high. Comments on this plan are open until February 23, 2026, so everyone has a chance to weigh in before it moves forward.

## Abstract

This proposed rule proposes to implement the Global Benchmark for Efficient Drug Pricing Model ("GLOBE Model"), a new Medicare payment model under section 1115A of the Social Security Act (the Act). The GLOBE Model would test whether a payment model that uses an alternative method for calculating Part B inflation rebate amounts for certain separately payable Part B drugs and biologicals products reduces costs for Medicare fee-for-service (FFS) beneficiaries and the Medicare program while preserving quality of care.

## Effects PRIA read

- Selected Medicare patients get lower coinsurance: benefit, medium. About 25 percent of traditional Medicare Part B fee-for-service beneficiaries in selected geographic areas would be placed in the GLOBE Model cohort. When those beneficiaries receive an included GLOBE Model drug on an applicable date of service, their coinsurance would be reduced (for example, CMS…
- Manufacturers must pay GLOBE rebates based on global prices: cost, high. CMS proposes mandatory participation for all manufacturers of Part B rebatable drugs that are designated as GLOBE Model drugs; those manufacturers would pay GLOBE Model rebates into the Medicare Part B account when the specified amount exceeds a benchmark based on international drug pricing. CMS st…
- CMS estimates multi-billion dollar Medicare savings: benefit, high. CMS estimates the GLOBE Model would reduce overall Medicare Part B net spending by $11.9 billion over the 7-year model period, including about $8.4 billion in Medicare Part B FFS savings, $7.5 billion in Medicare Advantage savings, and about $4.0 billion in premium offset impacts; CMS also estimate…
- CMS selects cohort; beneficiaries cannot appeal selection: mixed, medium. CMS would select which beneficiaries are in the GLOBE Model cohort (based on a beneficiary's address of record in selected geographic areas) and selection would not be subject to appeal; beneficiaries must have traditional Medicare Part B FFS as their primary payer and must not be enrolled in Medic…

## Related documents

- [2026-22792](https://policyrisk.com/federal-register/2026-22792): Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program, 2026-11-09
- [2026-22750](https://policyrisk.com/federal-register/2026-22750): Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the E…, 2026-11-09
- [2026-22743](https://policyrisk.com/federal-register/2026-22743): Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage…, 2026-11-09
- [2026-22739](https://policyrisk.com/federal-register/2026-22739): Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; i…, 2026-11-06
- [2026-22381](https://policyrisk.com/federal-register/2026-22381): Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage, 2026-11-03
- [2026-22194](https://policyrisk.com/federal-register/2026-22194): Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury (AKI) Dialysis Paym…, 2026-10-30

## Sources
- [2025-23702 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/23/2025-23702/global-benchmark-for-efficient-drug-pricing-globe-model)
- [2025-23702 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23702.pdf)

## Related
- [Previous: 2025-23693, Transparency in Coverage](https://policyrisk.com/federal-register/2025-23693)
- [Next: 2025-23704, Debt Collection Authorities Under the Debt Collection Improvement Act of 1996](https://policyrisk.com/federal-register/2025-23704)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-23702 (as of 2026-11-17).
